ImmunoGen Announces Webcast of Presentation and QA at Upcoming Canaccord Genuity 43rd Annual Growth Conference
IMGNDelisted Stock | USD 18.20 0.81 4.26% |
About 62% of ImmunoGen's investor base is looking to short. The analysis of current outlook of investing in ImmunoGen suggests that many traders are alarmed regarding ImmunoGen's prospects. ImmunoGen's investing sentiment overview a quick insight into current market opportunities from investing in ImmunoGen. Many technical investors use ImmunoGen stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
ImmunoGen |
ImmunoGen, Inc. , a leader in the expanding field of antibody-drug conjugates for the treatment of cancer, today announced that t
Read at businesswire.com
ImmunoGen Fundamental Analysis
We analyze ImmunoGen's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ImmunoGen using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ImmunoGen based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
ImmunoGen is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
ImmunoGen Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with ImmunoGen stock to make a market-neutral strategy. Peer analysis of ImmunoGen could also be used in its relative valuation, which is a method of valuing ImmunoGen by comparing valuation metrics with similar companies.
Peers
ImmunoGen Related Equities
XFOR | X4 Pharmaceuticals | 11.43 | ||||
MCRB | Seres Therapeutics | 6.52 | ||||
HEPA | Hepion Pharmaceuticals | 4.69 | ||||
ELEV | Elevation Oncology | 3.23 | ||||
PDSB | PDS Biotechnology | 1.86 | ||||
HOOK | Hookipa Pharma | 1.61 | ||||
MREO | Mereo BioPharma | 1.40 | ||||
AKRO | Akero Therapeutics | 0.22 | ||||
INZY | Inozyme Pharma | 0.37 | ||||
TGTX | TG Therapeutics | 0.57 | ||||
MDGL | Madrigal Pharmaceuticals | 0.98 | ||||
AXSM | Axsome Therapeutics | 1.44 | ||||
TERN | Terns Pharmaceuticals | 1.58 | ||||
VKTX | Viking Therapeutics | 2.88 |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Other Consideration for investing in ImmunoGen Stock
If you are still planning to invest in ImmunoGen check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the ImmunoGen's history and understand the potential risks before investing.
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Money Managers Screen money managers from public funds and ETFs managed around the world | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data |